Avience Biomedicals Ltd (AVIENCE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Avience Biomedicals Ltd on NSE and BSE, with an AI summary of each filing.
Avience Biomedicals Limited has informed the Exchange about Board Meeting to be held on 10-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 10 Nov 2026, 5:30 am
Avience Biomedicals Schedules Board Meeting for 10th Nov'26 to Consider Half-Yearly Results Avience Biomedicals Limited has notified the exchange that its Board of Directors will meet on 10th Nov'26. The board will inter-alia consider and approve the company's unaudited financial results for the half-year ended Sep'26.
To consider and approve the Standalone & Consolidated financial results for the period ended September 30, 2026
Intimation · 10 Nov 2026, 5:30 am
Avience Biomedicals Schedules Board Meeting for Half-Yearly Results Avience Biomedicals Limited has scheduled a meeting of its Board of Directors on 10th Nov'26 to consider, approve, and take on record the unaudited standalone and consolidated financial results for the half-year ended 30th Sep'26, alongside the Statutory Auditors' Limited Review Report. The board will also review certificates concerning the utilization of IPO proceeds and authorize key executives to submit the approved financial results and related documentation to the National Stock Exchange (NSE).
Avience Biomedicals Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q 30 September, 2026 FY 2026-27
Others (Uncategorized) · 29 Oct 2026, 12:23 am
Avience Biomedicals Confirms Corporate Governance Non-Applicability For Q2 FY27 Avience Biomedicals Limited notified the National Stock Exchange on 28th Oct'26 that corporate governance compliance provisions under SEBI (LODR) Regulations, 2015 are not applicable to the company for the quarter ended 30th Sep'26. As an entity listed on the NSE Emerge SME platform, the company is exempt under Regulation 15(2)(b), thereby removing the requirement to submit quarterly corporate governance reports. The filing was supported by a certification from practicing company secretary firm G.R. Gupta & Associates.
Avience Biomedicals Limited has informed the Exchange about Outcome of Investor Conference
Others · 02 Oct 2026, 1:31 am
Avience Biomedicals Concludes Participation in Arihant Bharat Connect Investor Conference Avience Biomedicals Limited informed the exchange that company management participated in the virtual 'Arihant Bharat Connect Conference Rising Star' hosted by Arihant Capital on 30th Sep'26 from 3:00 PM to 4:00 PM. Management engaged in discussions with investors and analysts during the session, and no Unpublished Price Sensitive Information (UPSI) was disclosed.
Avience Biomedicals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 01 Oct 2026, 11:46 pm
Avience Biomedicals Limited has informed the Exchange regarding Change in Auditors of the company.
Change in Auditor · 30 Sept 2026, 9:27 pm
Avience Biomedicals Approves Appointments of Statutory, Secretarial, and Internal Auditors Avience Biomedicals Limited announced that shareholders approved key auditor appointments at its 7th AGM on 30th Sep'26. M/s M.A.M AND ASSOCIATES, Chartered Accountants, has been appointed as Statutory Auditor from the conclusion of the 7th AGM until the 12th AGM, replacing retiring auditor M/s Haribhakti & Co. LLP. Additionally, M/s G R Gupta & Associates was appointed as Secretarial Auditor and M/s V C A N & CO LLP as Internal Auditor, both for five consecutive financial years covering FY27 to FY31.
Avience Biomedicals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Annual General Meeting · 30 Sept 2026, 9:03 pm
Avience Biomedicals Limited has informed the Exchange about Schedule of meet
Intimation · 23 Sept 2026, 8:36 pm
Avience Biomedicals Schedules Virtual Investor Meeting on 30th Sep'26 Avience Biomedicals Limited announced that company officials will attend the "Arihant Capital - Bharat Connect Conference: Rising Stars - September 2026" on 30th Sep'26 from 3:00 PM to 4:00 PM. The interaction will be a virtual group meeting pursuant to SEBI Listing Regulations. Discussions will strictly rely on publicly available information with no unpublished price-sensitive information (UPSI) involved.
Avience Biomedicals Limited has informed the Exchange regarding 'Intimation of AGM, Book Closure and cutoff date for evtoing'.
Annual General Meeting · 17 Sept 2026, 12:59 am
Avience Biomedicals Limited has informed the Exchange about advertisement of Post dispatch AGM Notice, Copy of Newspaper Publication
Annual General Meeting · 09 Sept 2026, 4:10 pm
Avience Biomedicals Limited has informed the Exchange regarding 'The Company has sent Letter to the Shareholder for AGM whose email id is not registered witht the Depository '.
Annual General Meeting · 09 Sept 2026, 4:54 am
Avience Biomedicals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
Annual General Meeting · 08 Sept 2026, 5:45 pm
Avience Biomedicals Limited has informed the Exchange regarding 'Avience Biomedicals Limited has informed the Exchange regarding 'Intimation of Annual General Meeting'.
Annual General Meeting · 08 Sept 2026, 4:48 pm
Avience Biomedicals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.
Outcome · 08 Sept 2026, 12:21 am
Avience Biomedicals Approves AGM Details, Auditor Appointments, and Asset Borrowing Powers Avience Biomedicals Limited’s board met on 7th Sep'26 and approved convening the 7th AGM on 30th Sep'26, with the book closure set from 24th Sep'26 to 30th Sep'26. The board recommended shareholder approval for appointing M/s M.A.M AND ASSOCIATES as Statutory Auditors for a five-year term (FY27 to FY31), replacing retiring auditors M/s HARIBHAKTI & CO. LLP, alongside appointing M/S. V C A N & CO LLP as Internal Auditors. Additionally, the board approved borrowing powers and asset mortgage/charge creation under Section 180 of the Companies Act, 2013.
Avience Biomedicals Limited has informed the Exchange about Board Meeting to be held on 07-Sep-2026 to consider Other business.
Intimation · 02 Sept 2026, 8:56 pm
Avience Biomedicals Schedules Board Meeting on 7th Sep'26 for Other Business Avience Biomedicals Limited will convene a board of directors meeting on the 7th Sep'26 to evaluate and discuss other business matters. Market participants should monitor the post-meeting disclosures for any strategic updates, corporate actions, or operational developments that could potentially impact the company's near-term outlook and stock performance.
To consider other business matters: To consider and approve the Notice of the ensuing AGM, Board s Report along with the requisite annexures for the financial year ended March 31, 2026.
Intimation · 02 Sept 2026, 8:51 pm
Avience Biomedicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome · 26 Aug 2026, 5:36 am
Avience Biomedicals Reports Revised FY26 Results Following IPO Avience Biomedicals' Board approved revised consolidated results for FY ended 31-Mar-26, showing PAT of ₹875.28 lakhs on revenue of ₹5,250.58 lakhs. This revision corrects an inter-company balance misstatement. The Board also appointed M/s G.R. Gupta & Associates as Secretarial Auditor for a five-year term. Subsequent to FY26, the company completed its IPO of 14,53,800 shares at ₹208/share, listing on the NSE EMERGE platform on 25-Jun-26. IPO proceeds will fund a new manufacturing unit, working capital, and general corporate purposes.
Avience Biomedicals Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q 30 June, 2026 FY 2026-27
Others (Uncategorized) · 30 Jul 2026, 2:00 am
Avience Biomedicals Confirms Exemption from Corporate Governance Norms Avience Biomedicals announced on 29 Jul'26 that Corporate Governance provisions under SEBI Listing Regulations are not applicable for the quarter ended 30 Jun'26. The exemption is due to its listing on the NSE Emerge (SME Platform) and meeting the criteria under Regulation 15(2)(b). A Practicing Company Secretary has certified the non-applicability. This exempts the company from filing reports related to regulations 17-27 for the specified quarter, simplifying its compliance burden.
Avience Biomedicals Limited has informed the Exchange about Transcript
Transcript · 29 Jul 2026, 5:08 am
Avience Biomedicals FY26 Results and Growth Outlook Avience Biomedicals reported FY26 revenue of ₹52.51 crore, with PAT growing 23.31% to ₹8.75 crore. EBITDA margin improved to 28.45% from 25.35% in FY25. Management guides for at least 60% revenue growth in FY27, supported by a ₹47 crore order book and a new manufacturing facility set to commence operations in Oct'26. The new facility has a potential revenue capacity of ₹250 crore. The company aims to shift its manufacturing-trading mix from 30:70 to 50:50 and is targeting ₹160-165 crore revenue in FY28.
Avience Biomedicals Limited has informed the Exchange about Link of Recording of con. call held as on 24.07.2026
Audio / Video · 25 Jul 2026, 9:46 pm
Avience Biomedicals Submits Audio Recording of H2 & FY26 Earnings Call Avience Biomedicals submitted the audio recording of its earnings call for the half-year and full-year ended Mar 31, 2026. The call with analysts and investors was conducted on Jul 24, 2026. The recording is available on the company's website, as per SEBI's Listing Obligations and Disclosure Requirements regulations.
Avience Biomedicals Limited has informed the Exchange about Investor Presentation
Investor Presentation · 24 Jul 2026, 6:55 pm
Avience Biomedicals FY26 Results and Growth Outlook Avience Biomedicals reported strong FY26 results with revenue growing 16.1% YoY to ₹5,250.6L and PAT up 23.3% to ₹875.3L. EBITDA margin improved to 28.45% from 25.35%. Management guides for at least 60% revenue growth in FY27, driven by a new ₹30.18 Cr automated facility (commissioning by Oct'26) and a recent ₹47.46 Cr PSU order executable in 3-4 months. The company plans to file for over 200 new product approvals to expand its portfolio from the current 88 CDSCO-approved products.
Avience Biomedicals Limited has informed the Exchange about Schedule of meet on earning conference call for investors Schedule on July 24 2026 at 04:00 P.M. (IST) to discuss the audited standalone and consolidated financials results of the company for the half year and financial year ended March 31, 2026
Intimation · 21 Jul 2026, 9:58 pm
Avience Biomedicals Schedules H2 & FY26 Earnings Call for 24 Jul'26 Avience Biomedicals (NSE: AVIENCE) has scheduled an investor conference call for 4:00 PM IST on 24 Jul'26. The management will discuss the audited standalone and consolidated financial results for the second half and the full financial year ended 31 Mar'26. The agenda includes a review of financial performance, business updates, key achievements, and the company's growth strategy and outlook, followed by a live Q&A session. This event is a key catalyst for near-term equity performance, pending the release of actual financial results.
To consider and approve the financial results for the period ended March 31, 2026
Financial Result · 14 Jul 2026, 3:36 pm
Avience Biomedicals Board Meeting to Approve FY26 Financial Results Avience Biomedicals has scheduled a Board of Directors meeting for 16th Jul'26 at 4:30 PM. The key agenda item is to consider and approve the audited standalone and consolidated financial results for the financial year ended 31st Mar'26. The board will also review the statutory auditors' report and authorize the submission of these results to the National Stock Exchange (NSE). The meeting will take place at the company's registered office in New Delhi.
To consider and approve the financial results for the period ended March 31, 2026
Financial Result · 13 Jul 2026, 9:01 pm
Avience Biomedicals Board to Approve FY26 Financial Results on 16th July Avience Biomedicals Limited has scheduled a Board of Directors meeting for 4:30 PM on 16th Jul'26. The key agenda is to consider and approve the audited standalone and consolidated financial results for the financial year ended 31st Mar'26. The board will also review the statutory auditors' report and authorize the submission of these documents to the National Stock Exchange (NSE). The meeting will take place at the company's registered office in Janakpuri, New Delhi.